Replimune Group (REPL) Competitors $4.53 -0.01 (-0.11%) As of 03:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock REPL vs. AVDL, JANX, EVO, RCUS, STOK, LENZ, SNDX, SION, XERS, and TSHAShould you be buying Replimune Group stock or one of its competitors? The main competitors of Replimune Group include Avadel Pharmaceuticals (AVDL), Janux Therapeutics (JANX), Evotec (EVO), Arcus Biosciences (RCUS), Stoke Therapeutics (STOK), LENZ Therapeutics (LENZ), Syndax Pharmaceuticals (SNDX), Sionna Therapeutics (SION), Xeris Biopharma (XERS), and Taysha Gene Therapies (TSHA). These companies are all part of the "pharmaceutical products" industry. Replimune Group vs. Its Competitors Avadel Pharmaceuticals Janux Therapeutics Evotec Arcus Biosciences Stoke Therapeutics LENZ Therapeutics Syndax Pharmaceuticals Sionna Therapeutics Xeris Biopharma Taysha Gene Therapies Replimune Group (NASDAQ:REPL) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability. Do analysts recommend REPL or AVDL? Replimune Group currently has a consensus target price of $6.50, indicating a potential upside of 43.65%. Avadel Pharmaceuticals has a consensus target price of $20.86, indicating a potential upside of 47.35%. Given Avadel Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Avadel Pharmaceuticals is more favorable than Replimune Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Replimune Group 3 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.91Avadel Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.70 Does the media prefer REPL or AVDL? In the previous week, Avadel Pharmaceuticals had 11 more articles in the media than Replimune Group. MarketBeat recorded 13 mentions for Avadel Pharmaceuticals and 2 mentions for Replimune Group. Replimune Group's average media sentiment score of 0.95 beat Avadel Pharmaceuticals' score of 0.12 indicating that Replimune Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avadel Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders believe in REPL or AVDL? 92.5% of Replimune Group shares are held by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are held by institutional investors. 5.2% of Replimune Group shares are held by company insiders. Comparatively, 5.2% of Avadel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is REPL or AVDL more profitable? Replimune Group has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -1.32%. Avadel Pharmaceuticals' return on equity of -3.73% beat Replimune Group's return on equity.Company Net Margins Return on Equity Return on Assets Replimune GroupN/A -69.34% -52.81% Avadel Pharmaceuticals -1.32%-3.73%-1.73% Which has more risk & volatility, REPL or AVDL? Replimune Group has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Which has preferable valuation & earnings, REPL or AVDL? Avadel Pharmaceuticals has higher revenue and earnings than Replimune Group. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReplimune GroupN/AN/A-$247.30M-$3.24-1.40Avadel Pharmaceuticals$169.12M8.13-$48.83M-$0.03-471.83 SummaryAvadel Pharmaceuticals beats Replimune Group on 11 of the 15 factors compared between the two stocks. Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REPL vs. The Competition Export to ExcelMetricReplimune GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$353.20M$3.34B$6.05B$10.45BDividend YieldN/A2.31%5.73%4.79%P/E Ratio-1.4022.2585.3627.06Price / SalesN/A419.31583.22188.54Price / CashN/A44.9825.7330.17Price / Book0.8410.4112.686.69Net Income-$247.30M-$52.31M$3.31B$276.12M7 Day Performance-3.31%0.67%-0.39%-1.29%1 Month Performance-21.03%13.90%8.76%6.30%1 Year Performance-60.58%28.53%76.60%34.03% Replimune Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REPLReplimune Group4.6715 of 5 stars$4.53-0.1%$6.50+43.6%-60.5%$353.20MN/A-1.40210AVDLAvadel Pharmaceuticals2.8205 of 5 stars$14.53-3.2%$20.86+43.5%+6.7%$1.46B$169.12M-484.3370JANXJanux Therapeutics2.5821 of 5 stars$22.76-5.2%$78.31+244.1%-46.5%$1.44B$10.59M0.0030EVOEvotec2.1926 of 5 stars$3.99-0.5%$5.40+35.3%+23.2%$1.42B$862.40M0.004,827RCUSArcus Biosciences1.9568 of 5 stars$14.54+8.9%$21.14+45.4%-20.0%$1.42B$258M-4.59500News CoverageAnalyst ForecastGap UpHigh Trading VolumeSTOKStoke Therapeutics2.9781 of 5 stars$26.81+4.9%$25.57-4.6%+155.0%$1.40B$36.56M30.07100Analyst ForecastInsider TradeLENZLENZ Therapeutics1.7328 of 5 stars$46.11-5.4%$49.60+7.6%+57.0%$1.39BN/A0.00110Analyst ForecastSNDXSyndax Pharmaceuticals3.6101 of 5 stars$16.40+5.1%$39.22+139.2%-16.0%$1.34B$23.68M0.00110SIONSionna Therapeutics2.6763 of 5 stars$29.25-2.5%$38.00+29.9%N/A$1.32BN/A0.0035XERSXeris Biopharma2.7494 of 5 stars$8.13-0.9%$7.08-12.9%+174.6%$1.32B$203.07M0.00290TSHATaysha Gene Therapies2.3503 of 5 stars$4.42-7.1%$9.00+103.6%+142.8%$1.30B$8.33M0.00180Positive News Related Companies and Tools Related Companies Avadel Pharmaceuticals Alternatives Janux Therapeutics Alternatives Evotec Alternatives Arcus Biosciences Alternatives Stoke Therapeutics Alternatives LENZ Therapeutics Alternatives Syndax Pharmaceuticals Alternatives Sionna Therapeutics Alternatives Xeris Biopharma Alternatives Taysha Gene Therapies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:REPL) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
